Medasense Biometrics Ltd., an Amat Gan, Israel-based medical device company developing a non-invasive, objective pain monitoring technology, completed a Series B financing round.
The amount of the deal was not disclosed.
Newest investor Baxter Ventures joined the recent round led by Benslie International Ltd. together with am undisclosed global medical technology corporation and other private investors.
The company will use the funds to continue global clinical research and market development of its flagship product PMD-200™.
Led by Galit Zuckerman, CEO and founder, Medasense is advancing PMD-200, an objective pain monitoring system for non-communicating patients in operating rooms and critical care, aiming to support clinicians in evaluating their patient’s pain level in order to optimize pain treatment.
Considering the complex nature of pain, the company developed the Nociception Level Index, the NoL™, based on a multi-parametric approach using artificial intelligence algorithms to determine a patient’s individual “Signature of Pain”.